glycine has been researched along with Immunologic Deficiency Syndromes in 9 studies
Immunologic Deficiency Syndromes: Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Pharmacokinetic parameters were determined after the third infusion of each product." | 2.71 | Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%). ( Ballow, M; Berger, M; Bonilla, FA; Buckley, RH; Cunningham-Rundles, CH; Fireman, P; Kaliner, M; Lathia, C; Ochs, HD; Skoda-Smith, S; Sweetser, MT; Taki, H, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (55.56) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballow, M | 1 |
| Berger, M | 1 |
| Bonilla, FA | 1 |
| Buckley, RH | 1 |
| Cunningham-Rundles, CH | 1 |
| Fireman, P | 1 |
| Kaliner, M | 1 |
| Ochs, HD | 1 |
| Skoda-Smith, S | 1 |
| Sweetser, MT | 1 |
| Taki, H | 1 |
| Lathia, C | 1 |
| Mancebo, E | 1 |
| Moreno-Pelayo, MA | 1 |
| Mencía, A | 1 |
| de la Calle-Martín, O | 1 |
| Allende, LM | 1 |
| Sivadorai, P | 1 |
| Kalaydjieva, L | 1 |
| Bertranpetit, J | 1 |
| Coto, E | 1 |
| Calleja-Antolín, S | 1 |
| Ruiz-Contreras, J | 1 |
| Paz-Artal, E | 1 |
| Shah, SR | 1 |
| Wallis, R | 1 |
| Cheng, JY | 1 |
| Khurnova, LM | 1 |
| Ivanitskaia, LP | 1 |
| Peters, DK | 3 |
| Williams, DG | 3 |
| Charlesworth, JA | 2 |
| Sissons, JG | 1 |
| Lachmann, PJ | 2 |
| Sherington, E | 1 |
| Alper, CA | 1 |
| Rosen, FS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Placebo-Controlled Trial of Intravenous Immunoglobulin (IVIG) for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections)[NCT01281969] | Phase 3 | 48 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Active IVIG will be significantly superior to sham IVIG in reducing OC symptoms and providing global relief of neuropsychiatric symptomatology. Total score is reported as the sum of all items and has a range of 0-40. Higher scores indicate more severe symptoms. (NCT01281969)
Timeframe: 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Group A | 20.59 |
| Group B | 25.67 |
1=very much improved, 2=much improved, 3=slightly improved, 4=no change, 5=slightly worse, 6=much worse, 7=very much worse (NCT01281969)
Timeframe: 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Group A | 2.88 |
| Group B | 3.53 |
"Defined as a CGI-I score of 1 or 2 (much or very much improved) and a decrease in CY-BOCS of at least 30%" (NCT01281969)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| Group A | 6 |
| Group B | 4 |
"Non-zero values of antinuclear antibodies are considered positive and reflective of an ongoing immune response in the individual. First, the number of participants who were classified at baseline as having positive antinuclear antibodies was calculated (see outcome measure data table, which states the number (AKA count) of participants who had positive antinuclear antibodies at baseline). We hypothesized that improvement in the ongoing immune response, and therefore a reduction in antinuclear antibody titers, would mediate the effect of IVIG on OCD symptom improvement. However, because very few participants were classified as positive at baseline, it was not appropriate to pursue the original question of whether a decline in antinuclear antibodies (i.e., from positive to negative) was related to symptom improvement." (NCT01281969)
Timeframe: Baseline
| Intervention | Participants (Count of Participants) |
|---|---|
| IVIG | 8 |
| Placebo | 5 |
4 reviews available for glycine and Immunologic Deficiency Syndromes
| Article | Year |
|---|---|
A newer immunoglobulin intravenous (IGIV) - Gammagard liquid 10%: evaluation of efficacy, safety, tolerability and impact on patient care.
Topics: Adolescent; Adult; Aged; Chemical Fractionation; Child; Clinical Trials, Phase III as Topic; Contrai | 2008 |
[Low-molecular weight immunomodulators of microbial origin].
Topics: Adjuvants, Immunologic; Amino Acids, Diamino; Animals; Antineoplastic Agents; Chemical Phenomena; Ch | 1989 |
Complement and mesangiocapillary glomerulonephritis role of complement deficiency in the pathogenesis of nephritis.
Topics: Animals; Antigen-Antibody Complex; Capillaries; Complement System Proteins; Feedback; Glomerulonephr | 1974 |
Genetic aspects of the complement system.
Topics: Agammaglobulinemia; Angioedema; Animals; Complement System Proteins; Genes; Glycine; Glycoproteins; | 1971 |
1 trial available for glycine and Immunologic Deficiency Syndromes
| Article | Year |
|---|---|
Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%).
Topics: Adult; Asthenia; Caprylates; Female; Glycine; Half-Life; Humans; Immunoglobulins, Intravenous; Immun | 2003 |
4 other studies available for glycine and Immunologic Deficiency Syndromes
| Article | Year |
|---|---|
Gly111Ser mutation in CD8A gene causing CD8 immunodeficiency is found in Spanish Gypsies.
Topics: Adolescent; CD8 Antigens; DNA Mutational Analysis; Female; Glycine; Haplotypes; Humans; Immunologic | 2008 |
Molecular defects in variant forms of mannose-binding protein associated with immunodeficiency.
Topics: Amino Acid Sequence; Amino Acid Substitution; Animals; Arginine; Aspartic Acid; Carrier Proteins; Co | 1999 |
Proceedings: Metabolism of C3 and glycine-rich beta glycoprotein (GBG) in hypocomplementaemia.
Topics: Complement System Proteins; Glycine; Glycoproteins; Humans; Immunologic Deficiency Syndromes | 1974 |
Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia.
Topics: Complement Inactivator Proteins; Complement System Proteins; Erythrocytes; Feedback; Glycine; Glycop | 1974 |